125,000 Shares in BioNTech SE Sponsored ADR $BNTX Purchased by Ghisallo Capital Management LLC

Ghisallo Capital Management LLC acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 125,000 shares of the company’s stock, valued at approximately $12,328,000. Ghisallo Capital Management LLC owned 0.05% of BioNTech as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vontobel Holding Ltd. boosted its stake in shares of BioNTech by 17.9% in the third quarter. Vontobel Holding Ltd. now owns 72,096 shares of the company’s stock valued at $7,110,000 after buying an additional 10,924 shares in the last quarter. Allianz SE grew its holdings in BioNTech by 635.0% during the second quarter. Allianz SE now owns 5,880 shares of the company’s stock worth $626,000 after acquiring an additional 5,080 shares during the period. Dodge & Cox purchased a new position in BioNTech in the second quarter worth $93,421,000. Lingohr Asset Management GmbH lifted its holdings in BioNTech by 598.4% in the third quarter. Lingohr Asset Management GmbH now owns 47,643 shares of the company’s stock valued at $4,699,000 after acquiring an additional 40,821 shares during the period. Finally, LBP AM SA lifted its holdings in BioNTech by 15.7% in the third quarter. LBP AM SA now owns 353,329 shares of the company’s stock valued at $34,845,000 after acquiring an additional 47,859 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Up 1.2%

Shares of NASDAQ BNTX opened at $91.19 on Friday. The firm’s 50-day moving average is $106.43 and its two-hundred day moving average is $102.56. The company has a market capitalization of $20.53 billion, a PE ratio of -17.40 and a beta of 1.51. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.02.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 price target on shares of BioNTech in a research note on Wednesday. Bank of America reissued a “buy” rating and set a $128.00 price objective on shares of BioNTech in a report on Tuesday. The Goldman Sachs Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a report on Friday, January 23rd. Finally, Morgan Stanley reduced their price target on shares of BioNTech from $134.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and an average target price of $133.73.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.